Healthcare / Pharmaceutical RetailersBSE
$212.00
-7.80 (-3.55%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $2.0M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$133M
P/E
N/A
•EV/EBITDA
N/A
•ROE
36.4%
↑Gross Margin
61.8%
↑Debt/Equity
-0.40
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+17.3%
FCF CAGR
—
FCF margin
-7.2%
FCF / Net income
0.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $59.2M · net income $-7.6M · FCF $-4.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $59.2M | $59.2M | $41.4M | $39.1M | $36.7M |
| Net Income | $-7.6M | $-7.6M | $7.3M | $2.1M | $4.3M |
| EBITDA | $-6.9M | $-6.9M | $8.0M | $3.0M | $5.5M |
| EPS | -12.11 | -12.11 | 11.65 | 3.40 | 6.96 |
| Gross Margin | 61.8% | 61.8% | 56.0% | 56.1% | 58.0% |
| Operating Margin | -16.6% | -16.6% | -0.9% | 1.0% | 4.6% |
| Net Margin | -12.8% | -12.8% | 17.6% | 5.4% | 11.8% |
| Balance Sheet | |||||
| Debt/Equity | -0.40 | -0.40 | -0.59 | -0.52 | -0.59 |
| Current Ratio | 0.54 | 0.54 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.2M | $-4.2M | $7.1M | $2.0M | $1.1M |
| Returns | |||||
| ROE | 36.4% | 36.4% | -56.1% | -10.5% | -19.5% |
| Valuation | |||||
| P/E | — | — | 17.35 | 54.32 | 18.10 |
| EV/EBITDA | — | — | 16.17 | 41.21 | 16.28 |
| Growth & Yield | |||||
| Revenue Growth | 42.9% | 42.9% | 5.8% | 6.7% | — |
| EPS Growth | -203.9% | -203.9% | 242.6% | -51.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.6%
Start / end P/E
n/dx → n/dx
EPS bridge
11.65 → -12.11
Residual
-9.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.